The International Liver Congress™ 2022 (ILC 2022)
London, UK (Hybrid) 22 June 2022 - 26 June 2022
Real-world studies demonstrate TAF efficacy and safety in chronic hep B
20 Jul 2022
byRoshini Claire Anthony
Treatment with tenofovir alafenamide (TAF) results in similar virological response compared with tenofovir disoproxil fumarate (TDF) in treatment-naïve patients with chronic hepatitis B (CHB), according to a real-world study from Korea presented at ILC 2022.
Real-world studies demonstrate TAF efficacy and safety in chronic hep B
20 Jul 2022
Unexplained hepatitis outbreak in kids: Are COVID-19, adenovirus the triggers?
19 Jul 2022
byElvira Manzano
Cases of acute, severe hepatitis of unknown aetiology in young children have increased recently and investigations are underway, says an expert during a media briefing at ILC 2022.
Unexplained hepatitis outbreak in kids: Are COVID-19, adenovirus the triggers?
19 Jul 2022
Resmetirom demos potential in NASH
18 Jul 2022
byRoshini Claire Anthony
Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.
